New York, New York--(Newsfile Corp. - December 31, 2024) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Outset Medical, Inc. (NASDAQ: OM) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Outset insiders caused the company to misrepresent or fail to disclose that (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the FDA; (2) that, as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) that there was a substantial risk that the Company would cease sales of the Tablo products pending FDA approval of additional indications; (4) that Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; (5) that, as a result of the foregoing, the Company's revenue growth would be adversely impacted; and (6) that, as a result of the foregoing, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you currently own OM and purchased prior to August 1 2022 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235661
